期刊文献+

头孢菌素类抗生素的药理特性及临床应用分析 被引量:15

Analysis of pharmacological characteristics and clinical application of cephalosporins antibiotics
下载PDF
导出
摘要 目的探索分析头孢菌素类抗生素的药理特性及临床应用。方法回顾性分析110例抗生素相关不良反应患者的临床资料,观察本组患者中由于头孢菌素类抗生素的应用而出现的不良反应的发生情况、累及部位等。结果 110例患者中由于应用头孢菌素类抗生素出现不良反应者45例,占总体的40.9%,累及的部位主要包括消化系统、神经系统、皮肤、皮肤附件等。结论应用头孢菌素类抗生素后,患者出现的不良反应主要涉及消化系统、神经系统、皮肤、皮肤附件等部位,因此在临床用药时,需要掌握药理特性,严密观察患者的临床症状和体征情况,以降低不良反应发生率,提高患者的治疗效果。 ObjectiveTo analyze pharmacological characteristics and clinical application of cephalosporins antibiotics.MethodsClinical data of 110 patients with antibiotics-related adverse reactions were retrospectively analyzed. Observation was made on adverse reactions and involved regions by cephalosporins antibiotics.ResultsThere were 45 cases with adverse reactions by cephalosporins antibiotics among 110 patients, accounting for 40.9%. Main involved regions included digestive system, nervous system, skin and appendages of skin.ConclusionCephalosporins antibiotics-induced adverse reactions mainly involve digestive system, nervous system, skin and appendages of skin. Therefore, understanding pharmacological characteristics and closely observing clinical symptom and vital signs can reduce incidence of adverse reactions and improve curative effects for patients.
作者 康庆
出处 《中国实用医药》 2016年第13期3-5,共3页 China Practical Medicine
关键词 头孢菌素类抗生素 药理特性 不良反应 临床应用 Cephalosporins antibiotics Pharmacological characteristics Adverse reactions Clinical application
  • 相关文献

参考文献7

二级参考文献32

  • 1蒋潇潇.第三代头孢菌素类药物的不良反应与防治[J].中国药房,2004,15(8):495-497. 被引量:54
  • 2俞森洋.头孢菌素类抗生素的临床应用[J].解放军保健医学杂志,2005,7(1):45-47. 被引量:7
  • 3张致平.抗生素结构修饰的进展[J].中国抗生素杂志,2006,31(2):90-99. 被引量:9
  • 4刘家健.头孢菌素类品种研发与生产现状探讨[J].中国抗生素杂志,2006,31(2):100-106. 被引量:16
  • 5张鸽.新型头孢菌素类抗生素[J].药学进展,2006,30(7):334-336. 被引量:1
  • 6Jack J C, Theresa M B, Joseph T W, et al. Randomized, prospective comparison of first-and second-generation cephalosporins as infection prophylaxis for cardiac surgery[J]. Am JSurg, 1993, 166(6): 734-737.
  • 7Stuart M H. Pharmacokinetics of the third-generation cephalosporins[J]. Am J Med, 1985, 79(2): 21-24.
  • 8Emirhan N, Sedef K, Doruk K, et al. Simultaneous roultiresponse optimization of an HPLC method to separate seven cephalosporins in plasma and amniotic fluid: Application to validation and quantification of cefepime, cefixime and cefoperazone[J]. Talanta, 2009, 80(1): 117-126.
  • 9Yoshizawa H, Kubota T, Itani H, et al. New broad-spectrum parenteral cephalosporins exhibiting potentactivity against both methicillin-resistant Staphylococcus aureus(MRSA ) and Pseudomonas aeruginosa. Part 2: Synthesis and Structure-activity relationships in the S-3578 series[J]. Bioorg Med Chem, 2004, 12:4211-4219.
  • 10Gasink L B, Fishrnan N O, Weiner M G, et al. Fluoroquinolone- resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact[J]. Am JMed, 2006, 119(6): 526.

共引文献152

同被引文献86

引证文献15

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部